Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity - 17/12/18
Abstract |
Objectives |
To determine the prevalence of nonalcoholic fatty liver disease (NAFLD) in children with obesity because current estimates range from 1.7% to 85%. A second objective was to evaluate the diagnostic accuracy of alanine aminotransferase (ALT) for NAFLD in children with obesity.
Study design |
We evaluated children aged 9-17 years with obesity for the presence of NAFLD. Diseases other than NAFLD were excluded by history and laboratories. Hepatic steatosis was measured by liver magnetic resonance imaging proton density fat fraction. The diagnostic accuracy of ALT for detecting NAFLD was evaluated.
Results |
The study included 408 children with obesity that had a mean age of 13.2 years and mean body mass index percentile of 98.0. The study population had a mean ALT of 32 U/L and median hepatic magnetic resonance imaging proton density fat fraction of 3.7%. The estimated prevalence of NAFLD was 26.0% (95% CI 24.2%-27.7%), 29.4% in male patients (CI 26.1%-32.7%) and 22.6% in female patients (CI 16.0%-29.1%). Optimal ALT cut-point was 42 U/L (47.8% sensitivity, 93.2% specificity) for male and 30 U/L (52.1% sensitivity, 88.8% specificity) for female patients. The classification and regression tree model with sex, ALT, and insulin had 80% diagnostic accuracy for NAFLD.
Conclusions |
NAFLD is common in children with obesity, but NAFLD and obesity are not concomitant. In children with obesity, NAFLD is present in nearly one-third of boys and one-fourth of girls.
Le texte complet de cet article est disponible en PDF.Keywords : pediatric, NAFLD, BMI
Abbreviations : ALT, AST, BMI, HDL, MRI, NAFLD, PDFF
Plan
This project was partially supported by the National Institutes of Health (NIH) Grants UL1TR000100 and UL1TR001442. The funders did not participate in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. M.M. consults for Bracco, Kowa, Median, Merge Healthcare, Novo Nordisk, and Quantitative Insights; is a stockholder with General Electric and Pfizer; and has grant funding from Gilead and Guerbet. C.S. has industry research support from Bayer, GE, Philips, and Siemens; consults for AMRA, Boehringer, and Guerbet; is on the speaker's bureau for Resoundant; and has lab service agreements with Gilead, ICON, Intercept, Shire, and Synageva. The other authors declare no conflicts of interest. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?